Open AccessA Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease
Author(s) -
Mahmoud Mosli,
Othman Alharbi,
Brian G. Feagan,
Majid A Almadi
Publication year - 2015
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/1319-3767.161635
Subject(s) - medicine , ulcerative colitis , inflammatory bowel disease , position statement , tumor necrosis factor alpha , position paper , gastroenterology , disease , tumor necrosis factor α , pediatric gastroenterology , crohn's disease , family medicine , pathology
The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents.